Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics & Specialty Pharmaceutical Distribu...
October 19 2020 - 8:00AM
Business Wire
Sesen Bio (Nasdaq:SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced that the Company has
selected Cardinal Health as its exclusive provider for third-party
logistics (3PL) and specialty pharmaceutical distribution services
related to the commercial distribution of Vicineum in the United
States (U.S.). The Company’s lead program, Vicineum, also known as
VB4-845, is currently in the follow-up stage of a Phase 3
registration trial for the treatment of high-risk, BCG-unresponsive
NMIBC. In December 2019, the Company initiated the BLA submission
for Vicineum to the U.S. Food and Drug Administration (FDA) under
Rolling Review.
Cardinal Health will provide comprehensive end-to-end 3PL,
order-to-cash management and specialty pharmaceutical distribution
services to Sesen Bio in support of commercialization in the U.S.
The Cardinal Health 3PL Services facility in LaVergne, Tennessee is
strategically located on the same site as the company’s specialty
pharmaceutical distribution operations and is also in close
proximity to a major FedEx shipping hub, which simplifies and
mitigates risk in supply chain operations.
Cardinal Health has deep experience in urology, as it currently
serves over 10,000 specialty clinics in the U.S. and has
relationships with more than 1,600 U.S.-based Urologists, which
will bring great value to Sesen Bio.
“Cardinal Health is an industry-leading warehouse operator and
distributor of specialty pharmaceuticals with an extensive oncology
portfolio, including Uro-oncology,” said Dr. Thomas Cannell,
president and chief executive officer of Sesen Bio. “Partnering
with Cardinal Health for both 3PL and specialty pharmaceutical
distribution services provides us with an integrated distribution
solution. In addition to Fujifilm and Baxter, the Cardinal Health
relationship completes the selection of major supply chain partners
in support of the commercial distribution of Vicineum. We are now
confident that the supply chain will be ready to support the
potential commercial launch of Vicineum in mid-2021.”
About Vicineum™
Vicineum, a locally administered fusion protein, is Sesen Bio’s
lead product candidate being developed for the treatment of
high-risk non-muscle invasive bladder cancer (NMIBC). Vicineum is
comprised of a recombinant fusion protein that targets epithelial
cell adhesion molecule (EpCAM) antigens on the surface of tumor
cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Vicineum is constructed with a stable, genetically engineered
peptide tether to ensure the payload remains attached until it is
internalized by the cancer cell, which is believed to decrease the
risk of toxicity to healthy tissues, thereby improving its safety.
In prior clinical trials conducted by Sesen Bio, EpCAM has been
shown to be overexpressed in NMIBC cells with minimal to no EpCAM
expression observed on normal bladder cells. Sesen Bio is currently
conducting the Phase 3 VISTA trial, designed to support the
registration of Vicineum for the treatment of high-risk NMIBC in
patients who have previously received a minimum of two courses of
bacillus Calmette-Guérin (BCG) and whose disease is now
BCG-unresponsive. Additionally, Sesen Bio believes that cancer
cell-killing properties of Vicineum promote an anti-tumor immune
response that may potentially combine well with immuno-oncology
drugs, such as checkpoint inhibitors. The activity of Vicineum in
BCG-unresponsive NMIBC is also being explored at the US National
Cancer Institute in combination with AstraZeneca’s immune
checkpoint inhibitor durvalumab.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing
targeted fusion protein therapeutics for the treatment of patients
with cancer. The Company’s lead program, Vicineum™, also known as
VB4-845, is currently in the follow-up stage of a Phase 3
registration trial for the treatment of high-risk, BCG-unresponsive
non-muscle invasive bladder cancer (NMIBC). In December 2019, the
Company initiated the BLA submission for Vicineum to the FDA under
Rolling Review. Sesen Bio retains worldwide rights to Vicineum with
the exception of Greater China, for which the Company has partnered
with Qilu Pharmaceutical for commercialization. Vicineum is a
locally administered targeted fusion protein composed of an
anti-EpCAM antibody fragment tethered to a truncated form of
Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For
more information, please visit the company’s website at
www.sesenbio.com.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: our ability to
successfully develop our product candidates and complete our
planned clinical programs, expectations regarding the potential
commercial launch of Vicineum in mid-2021, and other factors
discussed in the “Risk Factors” section of the Company’s Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and other
reports filed with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date hereof. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005026/en/
Erin Clark, Vice President, Corporate Strategy & Investor
Relations ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024